Phase 2 Data of AADvac1 in Alzheimer’s Disease Published
The tau vaccine evoked a robust anti-tau antibody response, which curbed the rise in plasma NfL and CSF p-tau over two years. Cognitive decline continued.
ALL NEWS
6537 RESULTS
Sort By:
- Most Recent
- Most Commented
Paper Alert: DIAN-TU Solanezumab and Gantenerumab Data Published
Though the first two trial arms were negative on cognition, gantenerumab’s strong effect on biomarkers led to an open-label extension.
Alzheimer's Association International Conference- 2021
Aducanumab: Will Appropriate-Use Recommendations Speed Uptake? On Donanemab, Plaques Plummet. Off Donanemab, They Stay Away Antisense Therapy Stifles CSF Tau in Mild Alzheimer’s Disease Seeking Real-World Data on Whether Aducanumab Works Will Insurance Co
Flurry of Investigations Besets Aducanumab
In the wake of the controversial thumbs-up for Aduhelm, the U.S. federal government is probing not only aducanumab’s price and approval history, but also the FDA’s accelerated approval pathway in general.
AL001 Boosts Progranulin. Does it Slow Frontotemporal Dementia?
In an open-label Phase 2 study, fluid biomarkers suggested the anti-sortilin antibody restored lysosomal function and reduced neuroinflammation in people with symptomatic FTD. Tantalizingly, participants worsened less than historical controls.
First Cognitive Signal that Tau Immunotherapy Works?
Topline results from a Phase 2 trial of semorinemab suggest the therapeutic antibody may have eased the cognitive downturn in people with mild to moderate Alzheimer’s disease.
Aβ, Tau, and Other AD Markers Altered in COVID
Markers of neuronal injury rose in plasma within a few months of severe COVID-19, then fell back to normal by six months. Some cases with brain symptoms had lower Aβ and higher tau in their blood.
NIA Funds Two New Alzheimer’s Disease Research Centers
North Carolina and South Texas centers to focus on risk factors and diversity.
Wolframin-1 Cells: Tau’s Launch Pad from Entorhinal Cortex to Hippocampus?
Misfolded tau travels from a subset of neurons in the entorhinal cortex directly into CA1 neurons in the hippocampus, fouling synaptic transmission and memory in mice.
AD Researchers Elected to National Academy of Medicine
The academy elected 90 new members. Five are well-known for their contributions to the field of neurodegenerative diseases.
Do Lipids Lubricate ApoE's Part in Alzheimer Mechanisms?
At a recent conference, researchers presented more evidence tying the APOE4 allele to disrupted lipid metabolism. They linked this problem to Aβ production.
When Abi3 Is a "No," Microglia Lose Their Get-Up-And-Go
In Alzheimer's mice without the AD risk gene Abi3, fewer microglia crowd around amyloid plaques. Cultured microglia without Abi3 appear stuck in a torpor, even though their phagocytosis mostly works.
First GWAS of Primary Age-Related Tauopathy Digs Up JADE
The new gene JADE1 encodes an adaptor protein that sits in tangles and nonetheless appears neuroprotective. The study also turned up three AD and two PSP genes, suggesting PART overlaps with these conditions.
Toxic Delivery: Do Microglia Unwittingly Sprinkle Aβ Around the Brain?
In a mouse model of amyloidosis, microglia carried Aβ aggregates into grafted wild-type tissue. The immune cells played a key part in the subsequent growth of plaques in the graft.
Brain Shuttle Could Halve Amount of Gantenerumab Needed
While Phase 3 trials of subcutaneous gantenerumab continue, scientists say delivering the antibody to the brain via the transferrin receptor might be twice as efficient.
Current Filters
No filters selected